Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy [4]

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 2, 2006, Pages 481-483

  Mariani, Paul G ^a,d   Sader, Helio S ^b   Jones, Ronald N ^b,c  

^a MeritCare Hospital   (United States)

^b JMI LABORATORIES   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclic lipopeptides; Glycopeptides; Resistance; S. aureus

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FLUCONAZOLE; GATIFLOXACIN; GENTAMICIN; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN G; PSEUDOMONIC ACID; RIFAMPICIN; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ACUTE CHOLECYSTITIS; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CASE REPORT; CATHETER INFECTION; CITROBACTER FREUNDII; CONTROLLED STUDY; DEATH; ENTEROCOCCUS FAECALIS; FEVER; HEART INFARCTION; HIP PROSTHESIS; HIP SURGERY; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LETTER; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PROSTHESIS INFECTION; STAPHYLOCOCCUS AUREUS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 33748034032     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl256     Document Type: Letter

References (6)

1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
2. Wootton M, Howe RA, Hillman R et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
3. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989; 33: 689-92.
4. Cui L, Tominaga E, Neoh HM et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
5. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005; 55 Suppl 2: Ii15-20.
6. Sakoulas G, Alder J, Thauvin-Eliopoulos C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.